Gilead Sciences, Inc. (GILD) vs Johnson & Johnson (JNJ)
Gilead Sciences, Inc. and Johnson & Johnson are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $652.8B against $183.2B — 3.6× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Johnson & Johnson trades at 31.4×. Johnson & Johnson grew revenue faster over the last twelve months: 8.06% against 5.52%. Johnson & Johnson has the higher net margin (21.5% vs −10.6%) and the higher return on invested capital (15.5% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (4.27% vs 3.07%). Across the 22 metrics below, Johnson & Johnson leads on 12 and Gilead Sciences, Inc. on 10.
Valuation
Profitability
| Metric | GILD | JNJ | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 67.91% | 72.77% |
| Operating margin | (8.20%) | 27.69% | 18.90% |
| Net margin | (10.64%) | 21.48% | 8.27% |
| Free cash flow margin | 42.50% | 23.20% | 17.25% |
| Return on equity | (20.68%) | 25.74% | 6.97% |
| Return on assets | (6.17%) | 10.67% | 2.76% |
| Return on invested capital | (4.48%) | 15.51% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack